Business Wire

Lineage Logistics Announces Acquisition of Kloosterboer Group

8.6.2021 20:32:00 EEST | Business Wire | Press release

Share

Lineage Logistics, LLC (“Lineage” or the “Company”), one of the world’s leading and most innovative temperature-controlled industrial REIT and logistics solutions providers, today announced it has reached an agreement to acquire Kloosterboer Group (“Kloosterboer”), a leading independent integrated platform for temperature-controlled storage, logistics and value-added services in Europe. The transaction is subject to regulatory clearance and completion of the employee consultation process.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005991/en/

Kloosterboer consists of eleven facilities across the Netherlands, France, Germany, Canada and South Africa, totaling 6.4 million cubic meters of capacity and 790,000 pallet positions and employing over 900 team members. A family-owned company with a rich legacy as a vegetable trading company dating back to 1925, Kloosterboer has grown over generations to become one of Europe’s best-known supply chain solutions companies. The Kloosterboer family will continue to be involved in the future of the Company, choosing to become investors in Lineage and rolling a part of their sale proceeds into Lineage equity.

“Welcoming Kloosterboer into the Lineage family marks a monumental step toward achieving our vision to become the world’s most dynamic temperature-controlled logistics company with the capability to serve customers in different countries around the world,” said Mike McClendon, Lineage’s President of International Operations & EVP of Network Optimization. “Kloosterboer’s strong entrepreneurial culture and management team, combined with their state-of-the-art, strategically located facility network perfectly complement Lineage’s international footprint and innovative spirit, which will deliver incredible value to our combined customers.”

In line with Lineage’s purpose of transforming the food supply chain to eliminate waste and help feed the world, Kloosterboer is recognized by BREEAM (Building Research Establishment Environmental Assessment Methodology) as a frontrunner in sustainable cold store operations. Kloosterboer’s network features nearly 18,000 solar panels, four wind turbines that power operations such as heavy lift equipment, and an annual reduction of CO2 equaling consumption of over 4,100 households.

“Kloosterboer has long focused on providing innovative and sustainable solutions, and we see great alignment with Lineage’s commitment to both the customer and the environment,” said the Kloosterboer family members. “We have known the founders of Lineage since 2014 and are confident Lineage is the right partner to help continue to serve our customers’ end-to-end logistical needs and accelerate the growth of Kloosterboer’s best-in-class capabilities. We are excited for a bright future full of opportunities for our team.”

Nielen Schuman acted as financial advisor to the Kloosterboer family and De Brauw Blackstone Westbroek served as its legal counsel. Rabobank acted as Lineage’s financial advisor and Latham & Watkins and Nauta Dutilh served as its legal counsel.

About Lineage Logistics

Lineage Logistics is one of the leading temperature-controlled industrial REIT and logistics solutions provider worldwide. It has a global network of over 350 strategically located facilities totaling over 2 billion cubic feet of capacity which spans 16 countries across North America, Europe and Asia-Pacific . Lineage’s industry-leading expertise in end-to-end logistical solutions, its unrivaled real estate network, and development and deployment of innovative technology help increase distribution efficiency, advance sustainability, minimize supply chain waste, and most importantly, as a Visionary Partner of Feeding America, help feed the world. In recognition of the company’s leading innovations and sustainability initiatives, Lineage was listed as No. 17 in the 2021 CNBC Disruptor 50 list, the No 1. Data Science company, and 23rd overall, on Fast Company’s 2019 list of The World’s Most Innovative Companies, in addition to being included on Fortune’s Change The World list in 2020. (www.lineagelogistics.com)

About Kloosterboer

The Kloosterboer Group is a family-owned company with more than 95 years of experience in the handling of temperature-controlled food products, such as fish, meat, fruit, fruit juices and fruit concentrates, dairy and potato products. Kloosterboer develops and provides innovative and sustainable solutions in the supply chain for conditioned food products. Kloosterboer is committed to long-term relationships, strives to achieve cost savings for its customers and increase the level of service. The company is specialised in warehousing, stevedoring, forwarding, shipping, customs and logistics IT. With storage capacity in The Netherlands, France, Germany, Canada and South Africa, Kloosterboer is one of the leading companies in this sector. (www.kloosterboer.com)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts:
Lineage Logistics
Megan Hendricksen
+1(949) 247-5172
mhendricksen@lineagelogistics.com

Kloosterboer Group
Uneke Dekkers
+31(0)650261626
uneke.dekkers@cffcommunications.nl

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye